|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An increase of 0.1 in NDVI corresponded to a reduction in SBP of 1.39 mmHg (95% CI: 1.86, -0.93) and lower odds of hypertension (OR = 0.76, 95% CI: 0.69, 0.82).
|
31672364 |
2020 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with high Hcy and MTHFR 667CC, as well as those with low Hcy and 667CT+TT, showed lower odds of uncontrolled SBP (MTHFR 667CC+ high Hcy: OR: 0.338, 95% CI: 0.115-0.996, Pcombined = 0.049; MTHFR 667CT/TT+ low Hcy: OR: 0.421, 95% CI: 0.193-0.921, Pcombined = 0.030) compared to patients with low Hcy and MTHFR 667CC.<b>Conclusions</b>: Serum Hcy status and Hcy metabolism gene polymorphisms (MTHFR C667T and MTRR A66G) may have synergistic effects on the prevalence of HTN and dyslipidemia.
|
30786773 |
2020 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Epidemiological studies reported an inconsistent association between stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) defined by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and cardiovascular disease (CVD) events.
|
31790053 |
2020 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
For subjects (n = 50) who exhibited uncontrolled morning hypertension (home systolic blood pressure [SBP]≥125 mmHg) at the end of study period I (at 8 weeks), nifedipine CR (20-40 mg) was added at bedtime, and rivaroxaban administration was continued an additional 8 weeks.
|
31542950 |
2020 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
To obtain inter-arm differences of SBP (the absolute difference of right and left arm) and ankle-brachial index, bilateral blood pressures were measured simultaneously at the four limbs using an automated oscillometric device in patients with treated hypertension (n = 234) and in normotensive subjects (n = 40).
|
31714348 |
2020 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We used inverse variance weighting (IVW) to assess the relation of HbA1c with risk of hypertension (defined using the American College of Cardiology/American Heart Association 2017 guidelines), and SBP and DBP.
|
31386636 |
2020 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
One-year hypertension remission and SBP and DBP pressure change at 1 and 5 years after both surgical techniques were also evaluated.
|
31633582 |
2020 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Participants with hypertension but without diabetes (N = 1167) were randomized to an SBP target below 120 mm Hg (intensive treatment) vs a target below 140 mm Hg (standard treatment).
|
31840813 |
2020 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Stage 2 hypertension (SBP/DBP ≥ 140/90 mmHg) showed significant associations with cardiovascular disease and all-cause mortality, while elevated blood pressure (SBP 120-129 mmHg and DBP < 80 mmHg) showed null associations.
|
31288541 |
2020 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Our aim was to assess the impact of cumulative SBP and SAEs on intensive hypertension treatment efficacy in the Systolic Blood Pressure Intervention Trial (SPRINT) population during follow-up.
|
30444838 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Multiple linear regression analysis revealed that baseline ABI was positively and independently associated with the yearly change in brachial SBP and hypertension incidence.
|
30640883 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypertension was defined as SBP at least 140 mmHg and/or DBP at least 90 mmHg, or current hypertension treatment, and was age-standardized to WHO world population.
|
30817448 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of subgroups showed that, there were statistically significant differences in the age of >50 years subgroup on ΔSBP [WMD = -2.32, 95% CI (-4.39, -0.25) P = .03]; there were statistically significant differences in the hypertension subgroup on ΔSBP [WMD = -6.58, 95% CI (-8.72, -4.44) P <.00001]; there were statistically significant differences in the hypertension subgroup on ΔDBP [WMD = -3.07, 95% CI (-4.66, -1.48) P = .0002]; there were statistically significant differences in the body mass index (BMI) >30 subgroup on ΔSBP [WMD = -3.51, 95% CI (-5.96, -1.07) P = .005].
|
31083159 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed the role of SBP VVV on the development of CKD in patients with type 2 diabetes (T2D) and hypertension in real life.
|
30624364 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Hypertension was defined as SBP at least 130 mmHg or DBP at least 80 mmHg, taking antihypertensive medicine or self-report.
|
31356404 |
2019 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
After stratifying the subjects according to blood pressure and blood glucose, the positive relationship between RHR and UACR remained in the subjects with normal blood pressure and normal glucose tolerance, while in the hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) group and the diabetic mellitus (FPG ≥ 7.0 mmol/L and/or PPG ≥ 11.1 mmol/L) group, the relationship disappeared.
|
31534974 |
2019 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mapuche and European schoolchildren show higher levels of SBP with a decrease in sleep time of 30 min; however, there is a higher prevalence of hypertension and obesity in ethnic Mapuches than in European schoolchildren.
|
31361065 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, the OR for hypertension in the third quartile of SHBG was lower than the highest quartile.
|
31096475 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The impact of SBP changes on eGFR was not significant; however, studies were of a relatively short duration.<b>Conclusion:</b> ARB had a favorable impact on BP and renal parameters such as proteinuria with monotherapy as well as with combination therapy, highlighting their potential benefits in patients with hypertension and CKD.
|
31392910 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
These trials - SPYRAL OFF-MED, RADIANCE SOLO and SPYRAL ON-MED - using newer technologies, demonstrate a 5-10 mmHg incremental reduction in ambulatory SBP from RDN against sham-control, in patients with mild-to-moderate hypertension taking 0-3 drugs.
|
31268917 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
A linear relationship was revealed between intradialytic SBP in IDH patients, indicating that the pre-HD and intra-HD SBP were correlated with post-HD SBP.
|
30325241 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
We defined hypertension as SBP of 140 mmHg or less and/or DBP of at least 90 mmHg, according to the 2010 Chinese guidelines for the management of hypertension.
|
30817449 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
SBP control rate among women with hypertension was the highest in 40-49 years (67.0%) but without linear trend by age group.
|
31190479 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The mean SBP greater than 120 mmHg had higher prevalence of cardiovascular risk factors, such as diabetes (38.4 vs. 27.2%, P = 0.001), hypertension (58.8 vs. 32.4%, P < 0.001), and chronic kidney disease (3.3 vs. 1.0%, P = 0.043) than mean SBP 120 mmHg or less.
|
31045965 |
2019 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This randomized-cross-over study included 38 patients (age: 60.4 ± 11.1 years, male: 65.8%) with intradialytic hypertension (intradialytic-SBP increase ≥ 10 mmHg at ≥4 over 6 consecutive sessions).
|
30622317 |
2019 |